Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 637 | Poster Presentation | Immune-related adverse events (irAEs) may indicate a favorable prognosis in metastatic renal cell carcinoma (mRCC) patients treated with immune checkpoint inhibitors (ICI) | Dylan J. Martini, BA; Sean T. Evans, BS; Subir Goyal, Ph.D; Yuan Liu, Ph.D; T. Anders Olsen, BA; Benjamin L. Magod, BS; Jacqueline T. Brown, MD; Lauren Yantorni, NP; Greta A. Russler, MSN, FNP-BC; Sarah Caulfield, PharmD, BCOP; Jamie M. Goldman, MD; Bassel Nazha, MD; Wayne B. Harris, MD; Viraj A. Master, MD Ph.D; Omer Kucuk, MD; Bradley C. Carthon, MD Ph.D; Mehmet A. Bilen, MD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Clinical study; Immune toxicity; Solid tumors |
| 638 | Poster Presentation | Plasma Proteome Analysis in Patients with Immune Checkpoint Inhibitors Related Arthritis and Pneumonitis | Noha Abdel-Wahab, MD, PhD; Adi Diab, MD; Hiroyuki Katayama, PhD; Sang Kim, MD, PhD; Samir M. Hanash, MD, PhD; Maria Suarez-Almazor, MD, PhD; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Proteomics |
| 639 | Poster Presentation | Immune-Related Thyroid Dysfunction in Patients with Existing Thyroid Dysfunction | Francois Kaleta, MD; Heather Brody, MD; Praveen Namireddy, MD; | Immunotherapy Toxicities | Checkpoint blockade; Immune monitoring; Immune toxicity; Solid tumors |
| 640 | Poster Presentation | Characterizing severe acute kidney injury in patients treated with immune checkpoint inhibitors | Chung-Jiah Chen, MD; Lisa Kim, M.S.; Ashley Weaver; Sandip P. Patel, MD; | Immunotherapy Toxicities | Immune toxicity |
| 641 | Poster Presentation | Incidence and risk factors for stroke associated with immune checkpoint inhibitor therapy in cancer patients using real-world clinical data | Prantesh Jain, MD FACP; Jahir Gutierrez, PhD; Avirup Guha, MD; Chhavi Jain, PhD; Nirav Patil; Tingke Shen; Ilya Stanevich; Ankit Mangla, MD; Marcos De Lima, MD; Jill Barnholtz-Sloan, PhD; Afshin Dowlati, MD; | Immunotherapy Toxicities | Checkpoint blockade; Chemotherapy; Immune monitoring; Immune toxicity; Solid tumors; Targeted therapy |
| 642 | Poster Presentation | Retrospective Review of Pulmonary Pathology Associated with Chimeric Antigen Receptor T Cell Therapy | Jing Du, MD; David W. Woolston; Kimberly E. Costas, MD; Alexandre Hirayama, MD; Cameron J. Turtle, MBBS, PhD; Cecilia CS. Yeung, MD; | Immunotherapy Toxicities | CAR T cells; Clinical study; Granulocyte; Immune toxicity; Leukemia/Lymphoma; Monocyte/Macrophage |
| 643 | Poster Presentation | Autopsy Review of Chimeric-Antigen Receptor T Cell Therapy: A Single Institution Experience | KiBeom Kwon; David W. Woolston; Alexandre Hirayama, MD; Damian Green, MD; David G. Maloney, MD, PhD; Cameron J. Turtle, MBBS, PhD; Cecilia CS. Yeung, MD; | Immunotherapy Toxicities | B cell; Biomarkers; CAR T cells; Clinical study; Cytokine; Immune toxicity; Leukemia/Lymphoma; T cell |
| 644 | Poster Presentation | Ocular adverse events associated with Programmed Death-1 and Programmed Death Ligand-1 immunotherapy | LeAnne H. Young, BS; Shanda Finnigan, MPH, RN; Howard Streicher, MD; Helen Chen, MD; James Murray, PhD; H. Nida Sen, MD, MHSc; Elad Sharon, MD, MPH; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Inflammation |
| 645 | Oral Presentation | Preclinical development of a novel colon-targeted therapeutic for the treatment of Immune Checkpoint Inhibitor (ICI)-colitis | Nazli Dizman, MD; Milton L. Greenberg, PhD; Andrew C. Newman, PhD; Jonathan Skupsky, MD, PhD; JoAnn Hsu, BS; Zeynep B. Zengin, MD; Nicholas Salgia, BS; Luis Meza, MD; Neal Chawla, MD; Sabrina Salgia; Jasnoor Kaur; Sumanta K. Pal, MD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Cytokine; Immune toxicity; Inflammation; Regulatory T cell (Treg cell); T cell |
| 646 | Poster Presentation | Evaluating a preclinical model of contact hypersensitivity for skin immune checkpoint toxicity | Barbara Ma, MD, MS; Abhinav Jaiswal, B.S.; K Sanjana P. Devi, PhD; Qingrong Huang, PhD; Joy Hsu, B.A.; Yong Liu, PhD; Niroshana Anandasabapathy, MD, PhD, MS; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 647 | Poster Presentation | Evaluation of efficacy and toxicity of CD137 immunotherapy with urelumab-mIgG1 chimeric antibody in CD137 HuGEMM™ | Hongjuan Zhang, PhD; Daniel X. He; Mingkun Zhang; Xinhe Feng; Annie X. An; Cunxiang Ju; Henry Q. Li; Davy X. Ouyang, PhD; | Immunotherapy Toxicities | Antibody; Immune toxicity; T cell |
| 648 | Poster Presentation | Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors | Kevin Tyan, BA; Joanna Baginska, PhD; Martha Brainard; Anita Giobbie-Hurder, MS; Mariano Severgnini, MSc; Michael P. Manos, BA; Rizwan Haq, MD, PhD; Elizabeth I. Buchbinder, MD; Patrick A. Ott, MD, PhD; F. Stephen Hodi, Jr., MD; Osama E. Rahma, MD; | Immunotherapy Toxicities | Biomarkers; Checkpoint blockade; Chemokine; Cytokine; Immune toxicity; Inflammation |
| 649 | Poster Presentation | Incidence of thromboembolism (TE) in patients with melanoma receiving immune checkpoint inhibitor (ICI) therapy and its adverse impact on survival | Tamara A. Sussman, MD; Joanna Roopkumar, MBBS, MPH; Hong Li, MS; Keith R. McCrae, MD; Pauline Funchain, MD; Alok A. Khorana, MD; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Inflammation; Solid tumors |
| 651 | Poster Presentation | NEUROLOGICAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: OUR EXPERIENCE IN A TERTIARY CARE CENTER | Pablo Alvarez-Ballesteros; Javier Buisan-Catevilla; Alvaro Beltrán-Corbellini; Iñigo Corral-Corral; Javier Pozas-Perez; Victor Albarran-Fernandez; Lucia Sanz-Gomez; Jorge Esteban-Villarrubia; Javier Torres-Jimenez; Jesús Chamorro-Perez; Diana Rosero-Rodriguez; María San Román-Gil; Ainara Soria-Rivas; | Immunotherapy Toxicities | Clinical study; Immune toxicity |
| 652 | Poster Presentation | Early Outcomes of an APP Acute Checkpoint Inhibitor (CPI) Care Clinic | Lisa Kottschade, NP, MS, RN; Casey Fazer; Anna Schwecke; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity |
| 653 | Oral Presentation | Dasatinib as a rapid pharmacological ON/OFF switch for T cell bispecific antibody-induced T cell activation and cytokine release | Gabrielle Leclercq, M. Sc. Eng.; Helene Haegel, PhD; Anneliese Schneider, PhD; Estelle Marrer Berger, PhD; Antje Walz, PhD; Christophe Boetsch, PhD; Vesna Pulko, PhD; Cristiano Ferlini, MD; Christian Klein, Dr rer nat; | Immunotherapy Toxicities | Antibody; Bispecifics; Cytokine; Immune suppression; Immune toxicity; Inflammation; T cell; Targeted therapy |
| 654 | Poster Presentation | Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors. | Nerea Lopetegui Lia, M.D.; Syed Imran Jafri; Khalid Shalaby; Dimitrios Drekolias; James Vredenburgh, M.D.; Nerea Lopetegui Lia, M.D.; | Immunotherapy Toxicities | Checkpoint blockade; Immune monitoring; Immune toxicity; Targeted therapy |
| 655 | Poster Presentation | Concordance Between Healthcare Providers and Expert Consensus Recommendations in the Management, Monitoring, and Mitigation of Adverse Events Associated with CAR T-Cell Therapy: An Updated Analysis | Matthew J. Frigault, MD, MSc; Megan Cartwright, PhD; Krista Marcello, BA; Timothy A. Quill, PhD; Daniel J. DeAngelo, MD, PhD; Ilene A. Galinsky, NP; Shilpa Paul, PharmD, BCOP; Jae H. Park, MD; Matthew J. Frigault, MD, MSc; | Immunotherapy Toxicities | CAR T cells; Cytokine; Immune toxicity; Leukemia/Lymphoma |
| 656 | Poster Presentation | Time to diagnostic clarity for suspected checkpoint-inhibitor pneumonitis in patients with lung cancer | Eric Olson, MD; Andrew Faucheux, MD; JiaHao Liang, MD; Janardhana Ponnatapura, MD; Jeffrey Lantz, DO; Nathan Roberts, MD; Andy Dothard, MD; Thomas W. Lycan, Jr., DO; Eric Olson, MD; | Immunotherapy Toxicities | Checkpoint blockade; Immune toxicity; Solid tumors |
| 657 | Poster Presentation | Interleukin-6 Receptor Blockade for Management of Immune Checkpoint Inhibitor Related Adverse Events in Patients with Melanoma | Chantal Saberian, MD; Faisal Fa'ak; Jean H. Tayar, MD; Maryam Buni, MD; Sang Kim, MD, PhD; Huifang Lu, MD, PhD; Maria Suarez-Almazor, MD, PhD; Stephen Gruschkus, PhD; May Daher, MD; Kaysia Ludford; Daniel Johnson, MD; Noha Abdel-Wahab, MD, PhD; Adi Diab, MD; | Immunotherapy Toxicities | Autoimmunity; Cytokine; Immune toxicity; Inflammation |
| 658 | Poster Presentation | Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases. | Sabina Sandigursky; Safa Houssein; Xerxes Pundole, MD, PhD; Elizaveta Efuni; Samuel Cytryn; Maryam Buni, MD; Anna C. Pavlick, MD, MBA; Michelle Krogsgaard, PhD; Chantal Saberian, MD; Mehmet Altan, MD; Maria Suarez-Almazor, MD, PhD; Jeffrey S. Weber, MD, PhD; Adi Diab, MD; Noha Abdel-Wahab, MD, PhD; | Immunotherapy Toxicities | Autoimmunity; Checkpoint blockade; Immune toxicity |
| 659 | Poster Presentation | Blocking Cytokine IL-1 with Anakinra for the Prevention of Cytokine Release Syndrome in COVID-19 | Erik R. Soule; Jason R. Williams, MD; Matthias Piesche; | Immunotherapy Toxicities | Clinical study; Cytokine; Immune toxicity; Targeted therapy |
| 853 | Poster Presentation | Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients. | Mohamed Eltahir, MD; Erika A. Fletcher, MSc; Linn Dynesius; Justina Jarblad; Martin Lord; Ida R. Olsson; Mikaela Zekarias; Xiaojie Yu; Mark Cragg; Caroline Hammarstom; Kerstin Hamberg Levedahl; Martin Höglund; Gustav J. Ullenhag, PhD, MD; Mattias Mattsson; Sara M. Mangsbo, PhD MSc; | Immunotherapy Toxicities | Antibody; Cytokine; NK/NK T cell |
| 854 | Poster Presentation | Prediction of severe immune-related adverse events in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the United States | Mark Kalinich, PhD; William Murphy, AB; Shannon Wongvibulsin, PhD; Vartan Pahalyants, BA; Kun-Hsing Yu, MD, PhD; Feicheng Wang, PhD; Leyre Zubiri, MD, PhD; Vivek Naranbhai, MBChB, PhD, DPhil; Alexander Gusev; Shawn G. Kwatra, MD; Kerry L. Reynolds, MD; Yevgeniy R. Semenov, MD, MA; | Immunotherapy Toxicities | Immune toxicity |
| 855 | Poster Presentation | Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses | Thomas K. Le; Subuhi Kaul, MD; Shannon Wongvibulsin, PhD; Laura Cappelli, MD; Jarushka Naidoo, MB BCH MHS; Yevgeniy R. Semenov, MD, MA; Shawn G. Kwatra, MD; | Immunotherapy Toxicities | Checkpoint blockade; Clinical study; Epidemiology; Immune toxicity |
| 856 | Poster Presentation | Preliminary review of Diabetes Mellitus incidence in patients treated with immune checkpoint inhibitors (ICI) therapy – Roswell Park Comprehensive Cancer Center (RPCCC) experience | Zhen Zhang, PharmD, BCPS; Grazyna Riebandt, PharmD, BCOP; Rajeev Sharma, MD, FACE; Jordan Scott, BS; Lamya Hamad, RPh, MPH; Laurie Plewinski, BS; | Immunotherapy Toxicities | Antibody; Autoimmunity; Checkpoint blockade; Immune toxicity; Solid tumors |
